ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:

Dictionar de medicamente online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dictionar medical online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Puteti trimite articole cu tema medicala la
adresa de email

Solutie antistress!
Construieste poduri :)
Joc, Construieste podul, Cargo Bridge

Prinde pisica neagra :)
Prinde pisica neagra- Chat Noir - Flash game

Castle Study Shows Boosted Reyataz(R) (Atazanavir) Is A Well Tolerated And Effective Option For Treatment-Naïve Patients

The week-48 results of the CASTLE study were announced at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) and showed boosted atazanavir to be as efficacious in antiretroviral-naive HIV-1 patients as lopinavir/ritonavir. In this study, 78 percent of patients (n=343/440) taking once-daily boosted atazanavir met the primary endpoint of achieving and maintaining an undetectable viral load (defined as less than 50 copies/mL) at 48 weeks, compared with 76 percent of patients (n=337/443) taking twice-daily lopinavir/ritonavir. Atazanavir is currently only licensed in the treatment of HIV-1 infected, antiretroviral treatment-experienced adults, in combination with other antiretroviral medicinal products.

This 96-week international study, being conducted at more than 130 sites in 30 countries, is comparing the antiretroviral efficacy and safety of once-daily boosted atazanavir (ATV/r) with twice-daily boosted lopinavir (LPV/r). Both treatments are being given concurrently with ritonavir, and each in combination with fixed-dose tenofovir (TDF) and emtricitabine (FTC) as a background therapy.

In the study, 74 percent of patients with high baseline viral load (greater than or equal to 100,000 copies/mL) who received once-daily ATV/r achieved and maintained an undetectable viral load at 48 weeks, versus 72 percent of patients who received twice-daily LPV/r. In a post hoc analysis of virologic responses by baseline CD4+ count, there was a statistically significant trend toward a lower response rate with lower CD4+ counts for LPV/r (p=0.0085). This trend did not occur with ATV/r.

Patients taking once-daily ATV/r experienced lower rates of diarrhoea and nausea compared with patients taking twice-daily LPV/r at 48 weeks (diarrhoea: 2% vs.11%; nausea: 4% vs. 8%, respectively). The results also demonstrated more favourable lipid effects with once-daily ATV/r as compared to the LPV/r arm. Treatment with once-daily ATV/r was associated with significantly lower mean percentage changes from baseline in total cholesterol (12% with ATV/r vs. 24% with LPV/r), triglycerides (13% vs. 51%) and non-HDL (7% vs. 21%) at 48 weeks (p





Castelul studiu aratã amplificat REYATAZ (R) (atazanavir) este o bine tolerat ºi eficientã opþiune pentru pacienþi netrataþi anterior - Castle Study Shows Boosted Reyataz(R) (Atazanavir) Is A Well Tolerated And Effective Option For Treatment-Naïve Patients - articole medicale engleza - startsanatate